Physician profile
Travis A Miller
NPI 1316958085
$272,999.14
in general payments reported to CMS, 2019-2025
24 companies · $71K in 2025
The $71K reported for 2025 was more than what 96% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88K · 2020: $6,438 · 2021: $11K · 2022: $9,971 · 2023: $24K · 2024: $62K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $108K · Consulting Fee: $24K · Travel and Lodging: $18K · Food and Beverage: $6,742 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,551.25 |
| Consulting Fee | $24,113.00 |
| Travel and Lodging | $18,359.80 |
| Food and Beverage | $6,741.87 |
| Education | $110.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $113,665.38 | 2019-2025 | Xolair |
| Astrazeneca Pharmaceuticals Lp | $105,763.89 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Novartis Pharmaceuticals Corporation | $25,308.85 | 2019-2025 | Xolair |
| Kaleo, INC. | $5,624.85 | 2019-2021 | |
| Genentech, INC. | $5,194.37 | 2019-2023 | Xolair |
| Optinose US, INC. | $4,246.53 | 2019-2022 | |
| Glaxosmithkline, LLC. | $3,812.65 | 2019-2025 | Nucala |
| Genzyme Corporation | $3,502.43 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,526.99 | 2019-2025 | Dupixent |
| Aquestive Therapeutics, INC. | $1,902.42 | 2025 | |
| Alk-Abello, INC | $339.98 | 2019 | |
| Sanofi-Aventis U.S. LLC | $310.21 | 2019-2023 | |
| Kyowa Kirin, INC. | $187.58 | 2025 | |
| Pharming Healthcare, INC. | $177.93 | 2023 | Ruconest |
| Blueprint Medicines Corporation | $124.99 | 2023 | Ayvakit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $74.30 | 2022-2023 | Takhzyro |
| Biocryst US Sales Co., LLC | $74.19 | 2025 | Orladeyo |
| Csl Behring | $50.80 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $29.63 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $27.60 | 2020 | |
| Electromed, INC. | $14.59 | 2025 | Smartvest |
| Eyevance Pharmaceuticals LLC | $13.50 | 2020 | |
| Covis Pharma Gmbh | $13.41 | 2020 | |
| Advanced Respiratory, INC | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.